基于硼替佐米化疗方案治疗多发性骨髓瘤的疗效与安全性分析
发布时间：2018-07-20 20:12
【摘要】：目的:探讨基于硼替佐米化疗方案治疗多发性骨髓瘤(multiple myeloma,MM)的疗效及安全性。方法:回顾性分析2009年11月-2016年11月住广西医科大学第一附属医院接受4个疗程及以上基于硼替佐米化疗方案的51例初治MM患者的临床资料,随访生存患者的基本情况,采用Kaplan-Meier法进行生存分析,采用Log-Rank检验分析确定影响预后的相关因素。结果:1、基于硼替佐米化疗方案治疗MM的疗效:(1)本组51例MM患者完成4周期化疗时评价疗效,全组患者的完全缓解率(Complete remission,CR)及总反应率(Overall response rate,ORR)分别为23.5%和86.3%;(2)本组患者3年生存率、5年生存率分别为68.7%和31.1%;(3)本组患者的中位总生存期(overall survival,OS)、中位无疾病进展生存期(progression free survival,PFS)分别为61个月和32个月。2、影响基于硼替佐米化疗方案治疗MM疗效的相关因素:(1)化疗取得CR及非常好的部分缓解(Very good partial remission,VGPR)患者组的PFS显著长于未取得VGPR组(40个月VS 16个月,P=0.001);(2)血清β2微球蛋白5.5mg/L患者组OS显著长于β2微球蛋白≥5.5mg/L患者组(76个月VS 37个月,P=0.004);(3)非重度贫血患者组OS显著长于重度贫血患者组(61个月VS 28个月,P=0.017);(4)DS分组中A组患者组OS显著长于B组患者组(61个月VS 17个月,P=0.001)。3、基于硼替佐米化疗方案治疗MM的的不良反应:(1)全组患者接受基于硼替佐米化疗方案化疗后不良反应发生率为70.6%;(2)全组患者主要不良反应包括白细胞减少、乏力、周围神经炎及感染,其发生率分别为23.5%,19.6%,17.6%及15.7%。结论:1、基于硼替佐米化疗方案治疗MM具有良好疗效;2、化疗后未取得VGPR、β2微球蛋白增高、重度贫血、肾功能损害的患者预后差;3、基于硼替佐米化疗方案治疗MM安全性好。
[Abstract]:Objective: to evaluate the efficacy and safety of bortezomib chemotherapy in the treatment of multiple myeloma (MM). Methods: the clinical data of 51 newly treated MM patients who were admitted to the first affiliated Hospital of Guangxi Medical University from November 2009 to November 2016 were analyzed retrospectively. Kaplan-Meier method was used for survival analysis and Log-Rank test was used to determine the related factors affecting prognosis. Results: (1) 51 patients with MM received 4 cycles of chemotherapy. The complete remission rate (CR) and total response rate (OR) were 23.5% and 86.3%, respectively; (2) the 3-year survival rate was 68.7% and the 5-year survival rate was 31.1%; (3) the median total survival time (overall survival OS) and the median disease-free progressive survival period (progression) in this group were 68.7% and 31.1% respectively; (3) the median survival time (progression) and the median survival time (progression) of the patients were 23.5% and 86.3%, respectively; (2) the 3-year survival rate was 68.7% and the 5-year survival rate was 31.1%, respectively. The free survival rate was 61 months and 32 months, respectively. The factors related to the efficacy of bortezomib regimen in the treatment of MM were as follows: (1) the patients with CR and very good partial remission (very good partial remissions) were significantly longer than those with no bortezomil (40 patients). The OS of serum 尾 2 microglobulin 5.5 mg / L group was significantly longer than that of 尾 2 microglobulin 鈮，
本文编号：2134642
[Abstract]:Objective: to evaluate the efficacy and safety of bortezomib chemotherapy in the treatment of multiple myeloma (MM). Methods: the clinical data of 51 newly treated MM patients who were admitted to the first affiliated Hospital of Guangxi Medical University from November 2009 to November 2016 were analyzed retrospectively. Kaplan-Meier method was used for survival analysis and Log-Rank test was used to determine the related factors affecting prognosis. Results: (1) 51 patients with MM received 4 cycles of chemotherapy. The complete remission rate (CR) and total response rate (OR) were 23.5% and 86.3%, respectively; (2) the 3-year survival rate was 68.7% and the 5-year survival rate was 31.1%; (3) the median total survival time (overall survival OS) and the median disease-free progressive survival period (progression) in this group were 68.7% and 31.1% respectively; (3) the median survival time (progression) and the median survival time (progression) of the patients were 23.5% and 86.3%, respectively; (2) the 3-year survival rate was 68.7% and the 5-year survival rate was 31.1%, respectively. The free survival rate was 61 months and 32 months, respectively. The factors related to the efficacy of bortezomib regimen in the treatment of MM were as follows: (1) the patients with CR and very good partial remission (very good partial remissions) were significantly longer than those with no bortezomil (40 patients). The OS of serum 尾 2 microglobulin 5.5 mg / L group was significantly longer than that of 尾 2 microglobulin 鈮，
本文编号：2134642
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2134642.html
